IL17A and metabolic dysfunction-associated steatohepatitis: NASH patients have higher plasma levels of IL-17A and IL-23 cytokines compared to CHC with significant fibrosis and cirrhosis, as well as serum and tissue IL-17A compared to CHC without significant fibrosis but with same stages of fibrosis, reflecting probable higher systemic multifactorial inflammation in NASH compared to CHC.